Therapeutic response of human tumor xenografts in athymic mice to doxorubicin

In order to establish the usefulness of the human tumor-nude mouse system as a predictive screen for anticancer agents, 17 tumors (3 breast, 3 colon, 3 lung, 3 melanoma, 2 ovary, 1 prostate, 1 sarcoma, and 1 larynx), serially transplantable in athymic mice, were used to study antitumor activity of d...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 1981-01, Vol.41 (1), p.325-335
Main Authors: Giuliani, F C, Zirvi, K A, Kaplan, N O
Format: Article
Language:English
Subjects:
Animals
Breast Neoplasms - drug therapy
Colonic Neoplasms - drug therapy
Doxorubicin - pharmacology
Female
Humans
Isoenzymes
L-Lactate Dehydrogenase - metabolism
Laryngeal Neoplasms - drug therapy
Lung Neoplasms - drug therapy
Male
Melanoma - drug therapy
Mice
Mice, Nude
Neoplasm Transplantation
Neoplasms, Experimental - drug therapy
Ovarian Neoplasms - drug therapy
Prostatic Neoplasms - drug therapy
Sarcoma - drug therapy
Transplantation, Heterologous
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In order to establish the usefulness of the human tumor-nude mouse system as a predictive screen for anticancer agents, 17 tumors (3 breast, 3 colon, 3 lung, 3 melanoma, 2 ovary, 1 prostate, 1 sarcoma, and 1 larynx), serially transplantable in athymic mice, were used to study antitumor activity of doxorubicin (Adriamycin). BALB/c nude mice were treated i.v. on a weekly basis for 3 to 4 weeks, starting when the tumor volume became relatively large (advanced stage of tumor treatment). All the tumors except lung tumor T 293 showed a 90 to 100% take rate and stable growth. Doxorubicin, at dose levels of 6 and 10 mg/kg/injection i.v. every week for 3 weeks, showed significant activity against all of the three breast tumors studied. As was expected on the basis of clinical data, doxorubicin showed no antitumor activity against the three different colon tumors. In the case of lung tumors, statistically significant activities against oat cell carcinoma T 293 and epidermoid carcinoma T 222 were observed. In contradiction to clinical data, doxorubicin was found to have significant activity against various melanomas studied and slight but not statistically significant activity against ovarian tumor T 17. Experimental results obtained using doxorubicin against prostate, sarcoma, and larynx tumors also parallel the reported clinical data.
ISSN:0008-5472
1538-7445